“The grim veil has been lifted.” Excitement, and questions, mount over Lilly’s positive Alzheimer’s drug data
Doctors, investors, and patient advocacy groups breathed a collective sigh of relief Wednesday morning after Eli Lilly broke its losing streak in its decades-long endeavor to treat Alzheimer’s disease.
The drug worked, and it looks comparable – and possibly competitive – to Leqembi, a similar therapy approved for treating the memory-robbing condition earlier this year.
“My first reaction was ‘phew.’ This is a great confirmation of data we saw from Leqembi,” Reisa Sperling, director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital in Boston, said in an interview with Endpoints News. “We’re on the right track.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters